This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated COL1A2 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-COL1A2 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~129.3 kDa | |
| Gel | 8–10% (standard starting point) | |
| Positive control | Cervix (IHC candidate; verify WB) +4 more | |
| Negative control | Suggested KO / knockdown lysate |
| PTM | Glycosylated + Cleaved | |
| Caveat | Processing-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
The A00624-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | various cells (catalog A00624-1) |
| Gel % | 8–10% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Wet/tank transfer; optimize duration (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A00624-1 · 1:500 (catalog A00624-1) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
COL1A2 has a predicted full-length mass of 129.3 kDa; cleavage and glycosylation could affect migration, but no empirical band position is supplied.
| Band near 129.3 kDa | Consistent with the predicted full-length precursor mass; confirm identity with a control |
| Band below 129.3 kDa | Could reflect signal-peptide or propeptide cleavage |
| Little or no band in whole-cell lysate | COL1A2 is secreted into the extracellular matrix |
| Band above 129.3 kDa | Glycosylation could affect migration, but no shift is established |
| Two bands at different positions | Could reflect precursor and processed forms; band identities need confirmation |
| Predicted full-length mass | 129.3 kDa is the sequence-based precursor reference |
| Signal peptide at residues 1–22 | Cleavage could yield a smaller product than the precursor |
| Propeptide at residues 23–79 | Cleavage could further reduce product size |
| Alternate O-linked galactosylation at hydroxylysine 177 | Could affect migration; a visible shift is not established |
| N-linked glycosylation at asparagine 1267 | Could affect migration; the size of any shift is unknown |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | COL1A2 is secreted into extracellular matrix | Examine extracellular or matrix material alongside a positive control |
| Band higher than expected | Glycosylation may affect migration, but its contribution is unconfirmed | Test glycosylation effects and verify band identity with an independent antibody |
| Band lower than expected | Signal-peptide or propeptide cleavage may reduce size | Compare precursor and extracellular samples and verify band identity |
| Multiple bands | Precursor and processed forms may coexist | Compare cellular and extracellular samples using a validated positive control |
| Weak or no signal | Secreted protein may be scarce in the sampled fraction | Enrich extracellular or matrix material and include a positive control |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cervix | glandular cells | High | Protein (IHC) | HPA → |
| Placenta | trophoblastic cells | High | Protein (IHC) | HPA → |
| Adipose tissue | adipocytes | Medium | Protein (IHC) | HPA → |
| Appendix | glandular cells | Medium | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Medium | Protein (IHC) | HPA → |
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | glandular cells | Low | Protein (IHC) | HPA → |
| Seminal vesicle | glandular cells | Low | Protein (IHC) | HPA → |
| Skeletal muscle | myocytes | Low | Protein (IHC) | HPA → |
| Smooth muscle | smooth muscle cells | Low | Protein (IHC) | HPA → |
| Spleen | cells in red pulp | Low | Protein (IHC) | HPA → |
Deeper troubleshooting and optimisation questions for COL1A2, answered from its protein features.
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Two the supplier anti-COL1A2 antibodies list Human, Mouse, and Rat reactivity and have WB images. Their captions report various cells at 1:500 and VEC cells at 1:1000; these examples do not establish performance across all specimens of the listed species.
Which to pick: Both have WB images and the same listed reactivity. A00624-1 shows various cells at 1:500; A00624 shows VEC cells at 1:1000. Choose based on which reported sample and conditions better match your experiment.